Compare Elastic NV (ESTC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Novo Nordisk A/S — how do they compare? Elastic NV trades at $77.12 (market cap $7.94B), while Novo Nordisk A/S trades at $46.43 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 26.2× Elastic NV's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| ESTC | NVO | |
|---|---|---|
Market Cap | $7.94B | $207.85B |
Sector | Technology | Health |
52-Week High | $94.47 | $63.98 |
52-Week Low | $43.30 | $35.29 |
Enterprise Value | $7.16B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic N.V. (ESTC) trades at $77.16, up 1.1% with a bullish technical outlook. The stock shows strong profitability with a 76.07% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include a collaboration with OpenAI and recognition as a leader in Gartner's Magic Quadrant for Observability Platforms. Institutional activity is mixed, with Amundi increasing its stake while BNY Mellon reduced its position.
The outlook is positive, supported by earnings momentum and strategic partnerships, but risks include high valuation multiples and a recent legal investigation. Analyst consensus is bullish with a $74.21 price target, though the current price exceeds this, indicating potential near-term consolidation. Revenue growth and AI integration present key opportunities for long-term investors.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
